Previous 10 | Next 10 |
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces that a Trial in Progress...
2023-05-04 13:56:05 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Most of the biggest biotech stocks on the market started off as unknown penny stocks . Look at Axsome Therapeutics (NASDAQ: AXSM ), for example. At one time, it was a $2.50 ...
Virtual webinar scheduled for Thursday, May 4 at 8:00 am pacific / 11:00 am eastern Meet with Atossa’s Founder and CEO, Steven Quay, M.D., Ph.D. Event is open to the public – registration available at ATOS5423.TribePublic.com SEATTLE, April 27, 2023 (GLOB...
2023-03-22 16:49:14 ET Atossa Therapeutics press release ( NASDAQ: ATOS ): FY GAAP EPS of -$0.21 beats by $0.01 . As of December 31, 2022, we had cash, cash equivalents and restricted cash of $111,000. Shares +2.53% . For further details see: Atossa T...
SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced financial results for the fiscal quarter and fiscal year ended...
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial PR Newswire SEATTLE and SAN FRANCISCO , March 21, 2023 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical ...
SEATTLE and SAN FRANCISCO, March 21, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, and Quantum Leap Healthcare Collaborative™ today announ...
SEATTLE, March 15, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced that the Company will present at the Sidoti Small-Cap Virtual ...
Atossa Therapeutics ( NASDAQ: ATOS ) is scheduled to announce FY22 earnings results on March 1st, before markets open. The consensus EPS Estimate is -$0.22 (-22.2% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 0 upward revisio...
SEATTLE, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today announces that the first patient has been dosed in the Phase 2 EVANGELINE ...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...